--- schema_version: "secwatch.filing_event.v1" accession: "0001213900-26-068264" form_type: "8-K" ticker: "ATRA" cik: "0001604464" company_name: "Atara Biotherapeutics, Inc." filed_at: "2026-06-12T20:05:45+00:00" generated_at: "2026-06-12T20:16:39.650874+00:00" event_type: "other_material" sentiment: "neutral" materiality_score: 0.3 calibrated_materiality_score: 0.3 confidence: "high" source: SEC EDGAR --- # Atara appoints Brian Cherry to board; annual meeting votes approve equity plan amendment ## Summary - Brian Cherry appointed as Class I director, effective June 11, 2026; also joins Audit Committee. - Initial RSU award of 24,000 shares vesting over 3 years; annual cash retainer $55,000. - Stockholders elected AnhCo Nguyen and Nachi Subramanian to board at June 9 annual meeting. - Advisory say-on-pay and amendment to 2024 Equity Incentive Plan (+400,000 shares) approved. - Deloitte & Touche ratified as independent auditor for fiscal year ending December 31, 2026. ## SEC filing metadata - accession: 0001213900-26-068264 - form_type: 8-K - ticker: ATRA - cik: 0001604464 - company_name: Atara Biotherapeutics, Inc. - filed_at: 2026-06-12T20:05:45+00:00 - event_type: other_material - sentiment: neutral - materiality_score: 0.3 - calibrated_materiality_score: 0.3 - confidence: high - sec_items: 5.02, 5.07 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1604464/000121390026068264/0001213900-26-068264-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604464/000121390026068264/ea0294561-8k_atara.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001213900-26-068264 - JSON: https://secwatch.observer/filing/0001213900-26-068264.json - Plain text: https://secwatch.observer/filing/0001213900-26-068264.txt ## Key facts - Executive change Brian Cherry was appointed as Class I Director at Atara Biotherapeutics, Inc.. - Action: appointed - Role: Class I Director source text: On June 11, 2026, the Board of Directors (the “ Board ”) of Atara Biotherapeutics, Inc. (the “ Company ”) appointed Brian Cherry to serve as a member of the Board as a Class I director, effective June 11, 2026 (the “ Effective Date ”). evidence_url: https://www.sec.gov/Archives/edgar/data/1604464/000121390026068264/0001213900-26-068264-index.htm - Shareholder Votes Atara Biotherapeutics, Inc. shareholders approved Ratification of appointment of independent registered public accounting firm at the 2026-06-09 meeting. - Proposal: auditor ratification - Outcome: passed - Meeting: 2026-06-09 source text: 4. Ratification of appointment of independent registered public accounting firm For Against Abstentions 6,490,311 29,237 1,504 The stockholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. evidence_url: https://www.sec.gov/Archives/edgar/data/1604464/000121390026068264/0001213900-26-068264-index.htm - Shareholder Votes Atara Biotherapeutics, Inc. shareholders approved Advisory vote to approve on the compensation of the Company's named executive officers at the 2026-06-09 meeting. - Proposal: say on pay - Outcome: passed - Meeting: 2026-06-09 source text: 2. Advisory vote to approve on the compensation of the Company’s named executive officers For Against Abstain Broker Non-Votes 3,526,411 44,481 4,532 2,945,628 The stockholders approved, on an advisory basis, the compensation awarded to the Company’s named executive officers, as disclosed in the Proxy Statement. evidence_url: https://www.sec.gov/Archives/edgar/data/1604464/000121390026068264/0001213900-26-068264-index.htm - Shareholder Votes Atara Biotherapeutics, Inc. shareholders approved Election of Directors at the 2026-06-09 meeting. - Proposal: director election - Outcome: passed - Meeting: 2026-06-09 source text: 1. Election of Directors Nominee For Withheld Broker Non-Votes AnhCo Nguyen Ph.D. 3,543,113 32,311 2,945,628 Nachi Subramanian 2,581,435 993,989 2,945,628 Each of the two nominees for director was elected to serve until the 2029 annual meeting of stockholders and until their respective successors are elected. evidence_url: https://www.sec.gov/Archives/edgar/data/1604464/000121390026068264/0001213900-26-068264-index.htm - Shareholder Votes Atara Biotherapeutics, Inc. shareholders approved Proposal to approve the first amendment to the Company’s 2024 Equity Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder by 400,000 at the 2026-06-09 meeting. - Proposal: equity plan - Outcome: passed - Meeting: 2026-06-09 source text: 3. Proposal to approve the first amendment to the Company’s 2024 Equity Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder by 400,000 For Against Abstain Broker Non-Votes 3,521,021 51,327 3,076 2,945,628 The stockholders approved the amendment to the Company’s 2024 Equity Incentive Plan, as disclosed in the Proxy Statement. evidence_url: https://www.sec.gov/Archives/edgar/data/1604464/000121390026068264/0001213900-26-068264-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.